Etalocib (LY293111) 是具有口服活性的白三烯(LTB4)受体的拮抗剂,抑制 [3H]LTB4结合的Ki值为 25 nM. Etalocib (LY293111) 抑制LTB4诱导的钙动员的lC50值为 20 nM。Etalocib (LY293111) 可诱导凋亡。
生物活性 | Etalocib (LY293111), an orally activeleukotriene B4receptorantagonist, inhibits the binding of[3H]LTB4, with aKiof 25 nM. Etalocib (LY293111) preventsLTB4-induced calcium mobilization with anlC50of 20 nM. Etalocib (LY293111) inducesapoptosis[1][2][3]. |
体外研究 (In Vitro) | Etalocib (LY293111) elicits a concentration-dependent inhibition of LTB4induced CD11b up-regulation[1]. Etalocib (LY293111) is an extremely potent and selective antagonist of human neutrophil function in vitro[2]. Etalocib (LY293111, 250 and 500 nM, 24-72 h) induces apoptosis and inhibits proliferation in human pancreatic cancer cells[3].
Cell Proliferation Assay[3] Cell Line: | MiaPaCa-2 and AsPC-1 human pancreatic cancer cells.[3] | Concentration: | 500 nM. | Incubation Time: | 24, 48, and 72 h. | Result: | Caused both a concentration-dependent and time-dependent inhibition of thymidine incorporation in both MiaPaCa-2 and AsPC-1 human pancreatic cancer cells. |
Apoptosis Analysis[3] Cell Line: | MiaPaCa-2 and AsPC-1 human pancreatic cancer cells. | Concentration: | 250 and 500 nM. | Incubation Time: | 24 h. | Result: | Induced apoptosis in human pancreatic cancer cells. |
|
体内研究 (In Vivo) | Etalocib (LY293111) produces a dose-related inhibition of acute leukotriene B4-induced airway obstruction when administered i.v. (ED50=14 μg/kg) or p.o. (ED50=0.4 mg/kg)[2]. Etalocib (LY293111, 10 mg/kg) inhibits A23187-induced lung inflammatory changes at 1 h[2]. Etalocib (LY293111, 250 mg/kg/day, orally) inhibits growth of human pancreatic cancer xenografts in athymic mice[3].
Animal Model: | Guinea pigs[2].
| Dosage: | 1-10 mg/kg. | Administration: | Orally once. | Result: | A single 1 mg/kg oral dose inhibited excised lung gas volume increases by 76.7±7.1% (n=4, P<0.002) when given 8 h prior to leukotriene B4challenge, and 28.6±20.3% (n=4, NS) when given 24 h before challenge. Had no effect (10 mg/kg) on pulmonary gas trapping at 1 h or 2 h after A23187 challenge. However, at 4 h, the pulmonary gas trapping response was significantly less than that of vehicle-treated controls and not different from sham values. The 10 mg/kg dose inhibited A23187-induced lung inflammatory changes at 1 h, but was without effect at 2 h or 4 h after challenge.
|
|
Clinical Trial | |
分子量 | |
性状 | |
Formula | |
CAS 号 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Powder | -20°C | 3 years | | 4°C | 2 years | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
溶解性数据 | In Vitro: DMSO : 100 mg/mL(183.62 mM;Need ultrasonic) 配制储备液 1 mM | 1.8362 mL | 9.1809 mL | 18.3618 mL | 5 mM | 0.3672 mL | 1.8362 mL | 3.6724 mL | 10 mM | 0.1836 mL | 0.9181 mL | 1.8362 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: 2.5 mg/mL (4.59 mM); Suspended solution; Need ultrasonic
此方案可获得 2.5 mg/mL (4.59 mM) 的均匀悬浊液,悬浊液可用于口服和腹腔注射。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 2. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 2.5 mg/mL (4.59 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (4.59 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。
*以上所有助溶剂都可在本网站选购。 |